电影票房

您好,歡迎訪問中山大學腫瘤防治中心官方網站!
職工郵箱 English
院士風采 首席專家 臨床專家 科研學者 客座教授 人才名錄 護理專家
首頁
  • 張力

    職務:內科主任,I期病房主任、中山大學肺癌研究所副主任
    職稱:教授、主任醫師、博士生導師、肺癌首席專家
    專長:擅長原發性肺癌、鼻咽癌的化學治療、靶向治療、免疫治療及多學科綜合治療
    姓名:張力
    職務:內科主任
    職稱:教授,主任醫師
    專長:在肺癌和鼻咽癌等實體瘤的化學治療、靶向治療、多學科綜合治療以及晚期癌癥的姑息治療等領域有較高造詣。對開展臨床研究具有豐富的經驗。
    出診時間:周一上午,周四上午

    學術兼職:
      中國抗癌協會腫瘤康復與姑息治療專業委員會候任主任委員
      中國抗癌協會臨床試驗專業委員會副主任委員
      中國臨床腫瘤學會(CSCO)常務理事
      CSCO-免疫治療專家委員會候任主委
      廣東省抗癌協會腫瘤化療專業委員會主任委員
      廣東省抗癌協會肺癌專業委員會副主任委員
      廣東省醫學領軍人才、“特支計劃”杰出人才(南粵百杰)
      國家重點研發計劃“精準醫學研究”肺癌的診療規范及應用方案的精準化研究項目負責人

    個人簡介:
      張力,教授、主任醫師、腫瘤內科博士生導師、肺癌首席專家、中山大學名醫、南粵百杰、國家重點研發計劃“肺癌精準醫學研究”項目(2016YFC0905500)負責人。現任中山大學腫瘤防治中心腫瘤內科主任兼I期病房主任、中山大學肺癌研究所副主任。1996年和1998年分別赴法國IGR和美國Fox Chase腫瘤中心短期進修。2001-2002年在美國MD Anderson腫瘤中心進修。
      擅長原發性肺癌、鼻咽癌的化學治療、靶向治療、免疫治療及多學科綜合治療。對抗癌新藥臨床研究的程序、原則、組織和實施亦有豐富經驗,主持多項國際多中心臨床研究和國家級多中心臨床研究。近年來在國際著名腫瘤學雜志如《柳葉刀》、《柳葉刀?腫瘤學》、《臨床腫瘤學》、《JAMA Oncology》、《腫瘤學年鑒》、《JNCI》、《JTO》等雜志發表SCI論著100余篇。研究成果多次在美國臨床腫瘤學年會、歐洲腫瘤內科學年會及世界肺癌大會進行大會口頭報告。獲國家科技進步二等獎、廣東省科學技術研究成果一等獎、廣東醫藥衛生科技進步獎三等獎各一次。
    姓名:張力
    職務:內科主任
    職稱:教授,主任醫師
    專長:在肺癌和鼻咽癌等實體瘤的化學治療、靶向治療、多學科綜合治療以及晚期癌癥的姑息治療等領域有較高造詣。對開展臨床研究具有豐富的經驗。
    出診時間:周一上午,周四上午

    學術兼職:
      中國抗癌協會腫瘤康復與姑息治療專業委員會候任主任委員
      中國抗癌協會臨床試驗專業委員會副主任委員
      中國臨床腫瘤學會(CSCO)常務理事
      CSCO-免疫治療專家委員會候任主委
      廣東省抗癌協會腫瘤化療專業委員會主任委員
      廣東省抗癌協會肺癌專業委員會副主任委員
      廣東省醫學領軍人才、“特支計劃”杰出人才(南粵百杰)
      國家重點研發計劃“精準醫學研究”肺癌的診療規范及應用方案的精準化研究項目負責人

    個人簡介:

      張力,教授、主任醫師、腫瘤內科博士生導師、肺癌首席專家、中山大學名醫、南粵百杰、國家重點研發計劃“肺癌精準醫學研究”項目(2016YFC0905500)負責人。現任中山大學腫瘤防治中心腫瘤內科主任兼I期病房主任、中山大學肺癌研究所副主任。1996年和1998年分別赴法國IGR和美國Fox Chase腫瘤中心短期進修。2001-2002年在美國MD Anderson腫瘤中心進修。
      擅長原發性肺癌、鼻咽癌的化學治療、靶向治療、免疫治療及多學科綜合治療。對抗癌新藥臨床研究的程序、原則、組織和實施亦有豐富經驗,主持多項國際多中心臨床研究和國家級多中心臨床研究。近年來在國際著名腫瘤學雜志如《柳葉刀》、《柳葉刀?腫瘤學》、《臨床腫瘤學》、《JAMA Oncology》、《腫瘤學年鑒》、《JNCI》、《JTO》等雜志發表SCI論著100余篇。研究成果多次在美國臨床腫瘤學年會、歐洲腫瘤內科學年會及世界肺癌大會進行大會口頭報告。獲國家科技進步二等獎、廣東省科學技術研究成果一等獎、廣東醫藥衛生科技進步獎三等獎各一次。


    海外留學經歷:
      1996年赴法國巴黎Institut Gustave Roussy(IGR)腫瘤中心短期進修。
      1998年赴美國費城Fox Chase腫瘤中心短期進修。
      2001-2002年在美國德州大學M.D.Anderson腫瘤中心進修。

    臨床醫療經驗:
        自1986年一直在中山醫科大學腫瘤防治中心從事腫瘤化療醫療、教學和科研工作及抗癌藥物的臨床研究,擅長肺癌、鼻咽癌和大腸癌等實體瘤的化學治療、靶向治療、多學科綜合治療。同時對晚期癌癥病人的對癥支持治療如:癌性貧血的治療、惡性腫瘤骨轉移的治療、化療導致的惡心嘔吐治療、晚期病人的疼痛的治療等方面也有較深入的研究。負責執筆撰寫中國版《NCCN非小細胞肺癌臨床指導原則》、《雙磷酸鹽治療肺癌骨轉移的專家共識》及《腫瘤相關貧血治療專家共識》等多個臨床共識,參與撰寫《NCCN結腸/直腸癌臨床指導原則》、《NCCN頭頸癌臨床指導原則》、《表皮生長因子受體抑制劑導致皮疹治療的專家共識》。在國內最早開展和應用放療前的誘導化療治療局部晚期鼻咽癌和大劑量醛氫葉酸+5FU持續滴注48小時(雙周療法)治療晚期大腸癌的臨床研究、非鉑類方案治療晚期非小細胞肺癌、分子靶向用于非小細胞肺癌的維持治療的臨床研究。在國內首創癌痛規范化治療示范病房(GPM)項目,并將該項目成功向全國推廣。目前擔任衛生部合理用藥專家委員會抗腫瘤藥專業組成員、衛生部癌痛規范化治療專家組副組長、廣東省干部保健專家、廣州市干部保健專家。

    科學研究經驗:
        對抗癌新藥臨床研究的程序、原則、組織和實施有非常豐富的實際操作經驗,主持或作為主要參與者的藥物臨床研究包括:卡鉑、長春瑞濱、多西紫杉醇、草酸鉑、馬藺子素膠囊、rhG-CSF、帕米磷酸二鈉、拓撲替康、吉非替尼、厄洛替尼、埃克替尼、阿帕替尼、法米替尼、昔妥西單抗、貝伐單抗、培美曲賽、S-1、血管內皮抑素等。直接參與一些國家創新(I類新藥)藥物(如:有機鍺、腫瘤壞死因子、基因工程溶瘤腺病毒H101、基因工程腺病毒-TK基因治療、埃克替尼、阿帕替尼、法米替尼、長效血管內皮抑素、氟拉哌索、Aflibercept)的藥代動力學研究和臨床試驗觀察工作。主持(PI)國際多中心臨床研究一項、國家級多中心臨床研究十多項,參與30多項國際多中心臨床研究、擔任多個國際多中心研究的獨立數據管理委員會(IDMC)成員和專家委員會(SC)成員。受國家藥品食品監督管理局(SFDA)委托負責起草《抗腫瘤藥物臨床研究技術指導原則》(2006年,第二版)。近年來分別承擔和參與了多項國家級科技攻關的科研基金(包括九五、十一五、1035計劃項目、863項目、973項目、新藥創制國家重大專項)、廣東省自然科學基金、廣東省重點科技攻關基金、廣東省醫學科研基金、廣州市科技局基金等研究。參與中山大學附屬腫瘤醫院國家級抗癌藥物臨床試驗研究中心的論證、籌建工作。成功組織和籌備每年度的廣東省抗癌協會化療專業委員會會議,以及國家級繼續教育項目GCP培訓班等。在SCI雜志發表論文40篇,其中包括第一作者或通訊作者的文章如:《Lancet Oncology》(SCI=22.589,第一及通訊作者)、《Journal of Clinical Oncology》(SCI=11.81,第一及通訊作者)、《Annals Oncology》(SCI=6.425,通訊作者)《European Journal of Cancer》(SCI=4.47通訊作者)、《Journal of Thoracic Cancer》(SCI=4.5通訊作者)、《Lung Cancer》(SCI=3.46,第一作者)、《Cancer Gene Therapy》(SCI=3.89,通訊作者)、《Cancer Chemotherapy and Pharmacology》(SCI=2.2,第一作者)等22篇,作為作者之一的文章如:《Journal of Clinical Oncology》(SCI=17.3)、《Lancet Oncology》(SCI=13.28)、《Cancer》(SCI=4.8)、《Journal of Thoracic Oncology》(SCI=3.5)、《Oncology》(SCI=1.9)、《Clinical Lung Cancer》等文章18篇。在國內核心期刊發表論文90余篇。主編及參與編寫腫瘤專業的專著有9本。獲廣東省科學技術研究成果三等獎(第一完成人)、廣東醫藥衛生科技進步獎三等獎(第四完成人)各一次。

    教學工作經驗
        自1986年至今一直在中山醫科大學腫瘤防治中心內科從事腫瘤化療本科生和進修醫生的臨床教學工作,擔任本科生臨床見習帶教兩次、1995年兼任本科生兼職班主任一次(一年)、一年制進修醫生班主任一次。從1997年擔任內科副主任后一直分管教學工作至2008年。1998年開始招收臨床型碩士研究生,現共培養臨床型碩士生12名、科研型碩士2名、七年制碩士3名、留學生1名。2009年開始招收博士研究生5名。獲中山醫科大學青年教師講課比賽三等獎一次。

    科研獲獎項目:
        1.《5-氟尿嘧啶/醛氫葉酸雙周療法治療惡性腫瘤》    廣東省科學技術研究成果三等獎,2006年度,排名第一
        2.《晚期鼻咽癌化學治療的研究》 廣東省醫藥衛生科技進步獎三等獎,1998年度,排名第四

    科研基金:

    2002年以前獲得獲得科研基金:
        1.廣東省醫學科研基金:重組腺病毒的藥代動力學及毒理學研究(A2001042)(2001-2003年)李蘇、張力、王安訓、廖海、何友兼
      2.廣東省醫學科研基金:5-FU靶酶及其代謝酶生物多態性與結直腸癌化療療效之相關性的研究(A2001222)(2001-2003年)張力、潘志忠、陳功、錢曉洲、夏忠軍、李蘇、廖海
      3.國家高技術研究發展計劃(“863”計劃):H101基因工程腺病毒的中試研究(分題)(102-1202-06)(2000-2002年)張力、徐瑞華、夏忠軍、廖海、李蘇
      4.國家醫藥技術創新項目:篩選逆轉腫瘤細胞對順氯氨鉑(DDP)的抗藥性逆轉劑(96-901-06-73)(2000-2001年)徐瑞華、符立梧、廖海、姜文奇、李蘇、梁永鉅、管忠震、張力
      5.廣州市科技計劃項目:粉防己堿臨床逆轉乳癌、骨肉瘤多藥抗藥性的研究(2000-Z-110-08)(2000-2003年)楊小平、姜文奇、沈靖南、符立梧、梁永鉅、張力、李蘇、王晉、蘇秀容、湯昊
      6.廣東省百項工程項目:新藥臨床試驗研究中心(GCP)(99B07902Q)(1999-2002年)姜文奇、張力、徐瑞華、劉冬耕、黃民、徐光川、黃慧強、譚悅、廖海、周中梅
      7.廣東省重點科技攻關項目:粉防已堿臨床逆轉腫瘤多藥抗藥性研究(99M04401G)(1999-2002年)符立梧、姜文奇、楊安奎、周晏、徐瑞華、張力、梁永鉅、潘啟超
      8.廣東省重點科技攻關項目:惡性淋巴瘤臨床特征與細胞周期調節蛋白及基因變異關系的研究(99M04911G)(1999-2002年)徐瑞華、姜文奇、邵建永、張力、孫曉非、周中梅、侯景輝、管忠震
      9.廣東省醫藥科研基金:彌漫性大B細胞淋巴瘤預后與細胞周期調控蛋白的關系(A1999208)(1999-2001年)徐瑞華、姜文奇、邵建永、周中梅、張力、喻慶薇、侯景輝

    2002年
      1.國家高技術研究發展計劃(863計劃):臨床試驗關鍵技術及平臺研究(2002AA2Z34IC)姜文奇、管忠震、張力、徐瑞華、夏忠軍、蘇蘇、黃民、劉冬耕、孫曉非、黃慧強、李志銘、李建紅、曹燁、郭穎
      2.廣東省醫學科研基金:I-III期非小細胞肺癌現代治療的新策略和多學科協作模式的建立(A2002229)王欣、張力、戎鐵華、盧泰祥、陳明、吳秋良、馬剛、林鵬、楊學寧、黃培鈺

    2004年
      1.廣東省科技計劃項目:組織微陣列方法分析NSCLC含鉑方案化療敏感性相關性研究(2004B30301006)張力、張陽、徐菲、李寧、李蘇、張星、廖海、汪波、侯景輝、郭穎
      2.廣東省科技計劃項目:N2期非小細胞肺癌新輔助治療策略的臨床研究(2004B30301008)王欣、戎鐵華、張力、陳明、鄭列、張惠忠、馬剛、王旭東、王春梅、王軍業

    2005年
      1.“985工程”二期建設項目:酪氨酸激酶抑制劑在鼻咽癌中應用的臨床與實驗研究。張力、黃培鈺、李蘇、張星、廖海、汪波、侯景輝

    2006年
      1.廣東省科技計劃項目:以分子標記物預測和預防非小細胞肺癌骨轉移的基礎和臨床研究  (2006B36002004)張力、王欣、汪波、云徑平、侯景輝、侯雪、林麗珊
      2.“十一五”國家科技支撐計劃:常見惡性腫瘤預防、早診及綜合治療研究項目非小細胞肺癌規范化多學科綜合治療的多中心協作研究(課題2)(主要參加人員)

    2007年
      1.廣東省自然科學基金:EGFR-TKI治療肺癌的基因組學及蛋白質組學研究(07001532)張力、王欣、李蘇、廖海、黃河、張陽、趙洪云、田瑩、林立平、吳烜
      2.國家高技術研究發展計劃(863計劃)課題:鼻咽癌的分子分型和個體化診療(2006AA02A404)(molecular classification, personalized diagnosis and therapy of nasopharyngeal carcinoma.)子課題:鼻咽癌個體化化療和分子靶向治療的探索。張力、李宇紅、麥海強、曹素梅、黃培玉、洪明晃、郭翔

    2008年
      1. 新藥創制國家重大專項:臨床試驗評價技術平臺(2008ZX09312-002)(Major science and technology project of "National Significant new drug creation")。子課題:新型靶向藥物臨床研究的探索
      2. 新藥創制國家重大專項:埃克替尼子課題(2008ZX09101-11):埃克替尼治療晚期非小細胞肺癌的II/III期臨床研究。張力、史艷俠、陳麗昆、黃巖

    2009年
      1.吳階平醫學基金會(08-JC-003):比較500mg吉非替尼與250mg吉非替尼用于經吉非替尼治療1月后疾病穩定的晚期非小細胞肺癌患者的隨機II期臨床研究(2009-2011)張力、鄧燕明、張為民、賈筠、董維(250萬)

    2010年
      1. CSCO血管靶向治療基金:腫瘤內微血管密度(MVD)預測貝伐單抗(Bev)聯合化療的療效的研究。(2010-2012)張力、陳麗昆、黃巖、梁穎(20萬)
      2. 廣州市科技計劃項目:FCγR基因多態性預測愛必妥治療NSCLC療效價值的臨床研究。(2010-2012)張力、史艷俠、陳麗昆、黃巖、田瑩、趙媛媛、蔣瑋、薛聰(15萬)

    2011年
      1. 廣東省衛生廳基金(A2011203):miR7與EGFR-TKI用藥療效相關性的實驗研究。(2010-2012)黃巖、趙洪云、田瑩、趙媛媛、薛聰、王樹森、張力(2萬)
      2. 勃林格殷格翰:BIBF1120治療鼻咽癌的臨床前研究
      3. 勃林格殷格翰:BIBW2992治療鼻咽癌的臨床前研究
      4. 吳階平醫學基金會(320672010015):Notch信號對非小細胞肺癌EGFR通路的調節作用及聯合靶向治療的機制研究。(2010-2011)謝勉,張力(7萬)
      5. 吳階平醫學基金會(320674010012):測定晚期NSCLC患者EGFR-TKI治療前后外周血EGFR下游通路蛋白表達變化與預測EGFR-TKI治療療效價值的研究。(2010-2012)黃巖、趙洪云、趙媛媛、薛聰、張力(7萬)
      6. 輝瑞制藥有限公司:c-met抑制劑在鼻咽癌中的體內體外研究

    2012年
      1. 國家自然科學基金青年科學基金項目(81201718):氟尿嘧啶相關酶調控作用下5FU劑量個體化治療模型的建立。(2013-2015)趙洪云、買世娟、趙媛媛、張劍威、黃巖、王志強、趙利平、田瑩、張力(23萬)
      2. 廣東省科技計劃項目(2012B031800280): 轉錄共活化因子p300在非小細胞肺癌侵襲性發展中的作用。(2013-2015)侯雪、楊浩賢、張力、孫健、吳烜、薛聰、趙媛媛、徐理華、羅容珍、侯景輝(5萬)
      3. 吳階平醫學基金會(?):腫瘤相關炎癥因子對表皮生長因子受體-酪氨酸激酶抑制劑治療非小細胞肺癌耐藥的影響及機制探討。(2012-2014)吳烜,張力(5萬)
      4. 廣東省自然科學基金(S2012040007455):氟尿嘧啶相關酶調控作用下鼻咽癌5FU劑量個體化治療模型的建立。(2012-2014)趙洪云、張劍威、趙媛媛、黃巖、王志強、趙利平、田瑩、張力(3萬)
      5. “863”高技術研究發展計劃資助重大項目:“重大疾病的分子分型與個體化診療技術”之“肺癌的分子分型和個體化診療技術”(2012AA02A502)(National High Technology Research and Development Program of China  2012AA02A502)子課題。張力、吳煊、胡志皇、方文峰、黃巖、趙洪云(30萬)
      6. “863”高技術研究發展計劃資助重大項目:“重大疾病基因組技術”和“分子分型與個體化診療技術”之“鼻咽癌的分子分型和個體化診療技術”(2012AA02A501)(National High Technology Research and Development Program of China  2012AA02A501)子課題。張力、黃巖、吳煊、胡志皇、方文峰、趙洪云(50萬)
      7. 國家科技重大專項項目:重大新藥創制之“基于高通量實時細胞篩選平臺和大容量化合物庫的新藥研發基地”(Innovative drug R&D center based on real-time high-throughput cell-based screening platformand large capacity compound library)之“分子靶點抗腫瘤新藥臨床研究”(2013ZX09401003-002)子課題。張力、李蘇、陳麗昆、趙洪云、趙媛媛、方文峰、畢炳添(200萬)

    2013年
      1. 吳階平基金課題(320.6750.1316):外周血腫瘤細胞計數及耐藥相關分子改變動態監測在EGFR突變陽性晚期非小細胞肺癌患者接受EGFR-TKI治療療效預測、評估及耐藥機制研究中的作用。張力、黃巖、方文峰、趙媛媛、吳煊、梁文華、田瑩、楊云鵬(200萬)


    主編或編寫專著:
      1.《實用頭頸腫瘤學》華南理工大出版社,1999年第一版,參加編寫,
      2.《臨床腫瘤學》(高校教材)科學出版社,1999年第一版,2005年第二版,參加編寫,ISBN 7-03-015941-1
      3.《社區腫瘤學》科學出版社,2000年第一版,參加編寫,2008年第二版,參加編寫 ISBN 978-7-03-022470-5
      4.《腫瘤化療處方手冊》廣東科技出出版社,2003第一版,2005年第二版,主編
      5.《腫瘤生物治療學》廣東科技出版社,2005第一版,參加編寫
      6.《食道胃腸道癌》(中國抗癌協會科普系列叢書)人民衛生出版社,2005第一版,參加編寫
      7.《臨床腫瘤學》(國家級繼續醫學教育項目教材)中國醫學電子音像出版社,2006第一版,參加編寫
      8.《腫瘤學專題講座》(名院學術廳叢書)鄭州大學出版社,2006第一版,參加編寫 ISBN 7-81106-266-6
      9.《乳腺癌肺癌骨轉移診療規范建議-專家共識解讀》(中華醫學繼續教育視聽雜志)中國醫學電子音像出版社,ISBN 7-900191-80-1/R?80,2006;主講
      10.《非小細胞肺癌規范診療進展》(中華醫學繼續教育視聽雜志)中國醫學電子音像出版社,ISBN 978-7-900220-71-4/R?71,2007;主講
      11.《惡性腫瘤骨轉移及骨相關疾病臨床診療專家共識》(2007年版)中國協和醫科大學出版社,ISRC CN-A37-07-0006-0/V.R(光碟版),2007;主講
      12.《惡性腫瘤骨轉移及骨相關疾病臨床診療專家共識》(2008年版)中國協和醫科大學出版社,ISRC CN-A37-08-0002-0/V.R(光碟版),2008;主講
      13.《惡性腫瘤骨轉移及骨相關疾病臨床診療專家共識》北京大學醫學出版社,2008年8月,第一版,ISBN 978-7-81116-125-0,參加編寫。
      14.《腫瘤分子靶向治療》人民衛生出版社,2009年5月,第一版,ISBN 978-7-711-11332-8,編委。
      15.《臨床腫瘤學高級教程》(高級衛生專業技術資格考試指導用書) 人民軍醫出版社,2011年11月,第一版,ISBN 978-7-5091-5170-9,編委。
      16.《肺癌》張蘭軍、張力主譯
      17.《個體化醫學原則》人民衛生出版社,2013年1月,第一版,ISBN 978-7-117-16476-4/R?16477,副主編。

    2002-2011年發表論文:
    第一作者或通訊作者:
      1. 鼻咽癌患者血漿EB病毒DNA水平的動態變化與臨床療效的關系.《癌癥》2002, 21(8):817-822
      2. HPLC法測定血漿中卡鉑的AUC.《中國臨床藥理學雜志》2002, 18(4):294-296
      3. 開普拓治療大腸癌的臨床應用.《中華腫瘤雜志》2003,25(6):607-609
      4. 吉西他濱加依托泊苷方案治療晚期非小細胞肺癌的II期臨床研究.《中國癌癥雜志》 2004, 14(1):59-60
      5. 鼻咽癌患者血漿EB病毒DNA水平的動態變化與腫瘤復發關系.《臨床腫瘤學雜志》2004, 9(2):122-125
      6. 晚期非小細胞肺癌組織中ERCC-1、Metallothionein、p53表達與鉑類耐藥性及預后的相關性分析.《癌癥》 2004, 23(7):845-850
      7. 吉西他濱聯合順鉑與吉西他濱聯合諾維本治療晚期非小細胞肺癌的臨床研究.《癌癥》2004, 23(11s):1455-1458
      8. 中國非小細胞肺癌患者表皮生長因子受體突變的研究.《癌癥》2005, 24(8):919-923
      9. Li Zhang, Chong Zhao, Pei-Jian Peng, Li-Xia Lu, Pei-Yu Huang, Fei Han, and Shao-Xiong Wu: Preliminary Results of Randomized Phase III ClinicalStudy Comparing Standard Radiotherapy With orWithout Weekly Oxaliplatin in Treatment ofLocoregionally Advanced Nasopharyngeal Carcinoma. Journal of Clinical Oncology 2005; Vol 23(33): 8461-8468(SCI=11.81)
      10. 晚期非小細胞肺癌治療新進展.《中國肺癌雜志》 2005, 8(5):375-377
      11. 吉西他濱聯合順鉑與吉西他濱聯合去甲長春堿方案治療非小細胞肺癌療效的比較.《中國肺癌雜志》 2005, 8(6):580-584
      12. 組織微陣列方法分析晚期非小細胞肺癌患者HER2蛋白表達及其臨床意義.《中國肺癌雜志》2006, 9(1):50-54
      13. Erlotinib在肺癌應用中的相關分子和臨床預后指標.《循證醫學》2006, 6(1):10-13
      14. 血漿EB病毒DNA濃度預測鼻咽癌遠處轉移的研究.《癌癥》 2006, 25(7):785-792
      15. 貝伐單抗與埃羅替尼聯合治療復發性非小細胞肺癌患者的I/II期臨床經驗.《循證醫學》2006, 6(4):213-215
      16. 國產多西紫杉醇治療晚期非小細胞肺癌的隨機對照臨床研究.《癌癥》2006, 25(8):999-1002
      17. 重組人紅細胞生成素大劑量沖擊維持療法治療30例腫瘤相關貧血的臨床報告.《癌癥》 2006, 25(9):1120-1122
      18. Gefitinib記名供藥計劃(EAP)治療晚期非小細胞肺癌患者的臨床研究結果.《癌癥》2006, 25(12):1561-1564
      19. 原發性小腸腺癌 50例臨床分析.《臨床腫瘤學雜志》 2006, 11(5):358-360
      20. 放射治療同期合并每周奧沙利鉑治療局部晚期鼻咽癌的隨機Ⅱ期臨床對照研究.《中國腫瘤臨床》 2006, 33(17):995-998
      21. 非小細胞肺癌輔助化療的熱點問題.《中華結核和呼吸雜志》2007, 30(2):86-87
      22. Bijesh Raj Ghimire,林立平,郭穎,張力:同期化放療與單純放療在局部晚期鼻咽癌中的作用:一項關于III期隨機試驗的薈萃分析.《循證醫學》2007, 6(4):213-215
      23. 吉非替尼治療化療失敗的局部晚期或轉移性非小細胞肺癌療效及生存的預測因素.《中國肺癌雜志》 2007, 10(5):411-417
      24. Li Zhang, Yang Zhang, Pei-Yu Huang, Fei Xu, Pei-Jian Peng, Zhong-Zhen Guan: Phase II Clinical Study of Gemcitabine in the treatment of patients withadvanced nasopharyngeal carcinoma (NPC) after the failure of platinumbased chemotherapy. Cancer Chemotherapy and Pharmacology2008; Vol 61(1):33-38(SCI=2.2)
      25. 應用熒光原位雜交方法檢測鼻咽癌細胞系中 EGFR基因拷貝數變化.《實用癌癥雜志》2008, 23(4):390-392
      26. 晚期非小細胞肺癌一線化療療效與生存關系的分析.《中國肺癌雜志》2008, 11(3):333-338
      27. 晚期非小細胞肺癌的二線治療進展.《中國肺癌雜志》 2008, 11(1):4-9
      28. 厄羅替尼治療晚期非小細胞肺癌患者的臨床療效.《癌癥》 2008, 27(4):393-399
      29. 非小細胞肺癌小腸轉移1例報告和文獻復習.《癌癥》2008, 27(4):447-448
      30. 化療在不可切除III期(N2)非小細胞肺癌中的作用.《中國肺癌雜志》 2008, 11(5):657-662
      31. Relationship between expression of CEA, E-cadherin and liver metastasis in colorectal cancer. Chinese Journal of Clinical Oncology 2008; Vol 5 (6):429-432
      32. 組織芯片技術分析c-kit蛋白在鼻咽癌組織中的表達及其臨床意義 .《臨床腫瘤學雜志》2009, 14(2):97-101
      33. C-KIT基因在鼻咽癌患者中的突變.《中國癌癥雜志》2009, 19(4):266-269
      34. 鼻咽、肺雙原發癌一例病例報告和文獻復習.《中國肺癌雜志》 2009, 12(1):86-89
      35. 吉非替尼對鼻咽癌細胞抑制作用及其對 EGFR 表達影響的探討.《中華腫瘤防治雜志》 2009, 16(13):978-981
      36. Xu Fei, Li Su, Li Xiao-ling, Guo Ying, Zou Ben-Yan, Xu Ran, Liao Hai, Zhao Hong-Yun, Guan Zhong-Zhen, Zhang Li: Phase I study of Recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and Ganciclovir administration in patients with malignant tumor. Cancer Gene Therapy 2009; Vol 16:723-730(SCI=3.89)
      37. Li Zhang, Xue Hou, Shun Lu, Huilan Rao, Jinghui Hou, Rongzhen Luo,He Huang, HongyunZhao, Hong Jian, Zhiwei Chen, Meilin Liao, Xin Wang: Predictive significance of bone sialoprotein and osteopontin for bone metastases in resected Chinese non-small-cell lung cancer patients: A large cohort retrospective study. Lung Cancer 2010; Vol 67:114-119(SCI=3.14)
      38. 鼻咽癌細胞株中C-Kit表達和突變以及對Imatinib的反應性.《癌癥》 2010; 29(2):137-142
      39. Wei Jiang, Yang Zhang, Hongyun Zhao, Guangchuan Xu, Liping Lin, Yuanyuan Zhao, Cong Xue, Li Zhang:Immediate Versus Delayed Topotecan after First-line Therapy in Small Cell Lung Cancer.Chinese Journal of Lung Cancer2010;Vol 13(3):211-215
      40. RRM1和 ERCC1對早期非小細胞肺癌術后生存的預測作用. 《循證醫學》 2010, 10(1):17-22
      41.非小細胞肺癌患者K-RAS基因突變的研究.《中國肺癌雜志》2010, 13(6):602-606
      42. Wang, Fenghua; Jiang, Fanggong; Li, Yuhong; Guo, Ying; Shen, Lin; Zhang Li:The Role of Oxaliplatin-Based Versus Cisplatin-Based Regimens in AdvancedGastric Cancer: A Systematic Review and Pooled Analysis of theChinese Literature. Current Cancer Therapy Reviews 2010;Vol 6 (3):214-221.
      43.  Liang-ping Xia; Hui-juan Qiu; Xu-xian Chen; Pi-li Hu; Gui-fang Guo; Fang Wang; Fei-fei Zhou; Wen-zhuo He; Bei Zhang; Li Zhang: Short-term outcomes of cetuximab combined with standard chemotherapy as first line setting for Chinese patients with Non-small cell lung cancer: a report of 12 cases. Medical Oncology2010; Vol28(1):570-576 (SCI=1.227)
      44. Li Zhang, Chong Zhao, Bijesh Ghimire, Ming-Huang Hong, Qing Liu, Yang Zhang, Ying Guo,Yi-Jun Huang, Zhong-Zhen Guan:The Role of Concurrent Chemoradiotherapy in the Treatment of Locolregionally Advanced Nasopharyngeal Carcinoma among Endemic Population: A Meta- analysis of the Phase III Randomized Trials. BMC Cancer 2010; Vol 10:558 (SCI=2.74)
      45. Li Zhang, Su Li, Yang Zhang, Jing Zhan, Ben-Yan Zou, Robert Smith, Paul D Martin, Yinrui Jiang, Hai Liao, Zhong-zhen Guan: Pharmacokinetics and Tolerability of Vandetanib in Chinese Patients With Solid, Malignant Tumours: An Open-Label, Phase I, Rising Multiple Dose Study. ClinicalTherapeutics, 2011; Vol 33(3): 315–327 (SCI=3.28)
      46.Xue Hou, Chong Zhao, Ying Guo, Fei Han, Li-Xia Lu, Shao-Xiong Wu, Su Li, Pei-Yu Huang, He Huang, Li Zhang:Different Clinical Significance of Pre- and Post-treatment Plasma Epsteine Barr Virus DNA Load in Nasopharyngeal Carcinoma Treated with Radiotherapy. Clinical Oncology 2011; Vol 23: 128-133 (SCI=2.85)
      47.Yuan-Yuan Zhao, Cong Xue, Xue Hou, Hai Liao, Su Li, Hong-Yun Zhao, YanHuang, Li-Kun Chen, Fei Xu, Jun-Ling Liu, Li Zhang: Changes of bone resorption marker (NTX) in chemotherapy plus zoledronic acid versus chemotherapy alone for nasopharyngeal cancer patients with bone metastases. European Journal of Cancer 2011; Vol 47:848-853 (SCI=4.47)
      48.Fenghua Wang, Yang Zhang, Hongyun Zhao, Likun Chen,Yan-Xia Shi, Li Zhang:Validation of a clinical prognostic modelinChinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib.Medical Oncology 2011; Vol28(1):331-5(SCI=2.21)
      49.Yuan-Yuan Zhao, Su Li, Yang Zhang, Hong-Yun Zhao, Hai Liao, Ying Guo, Yan-Xia Shi, Wei Jiang, Cong Xue, Li Zhang:The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib. Medical Oncology 2011; Vol 28(3):697-702(SCI=2.21)
      50.Yuan-Yuan Zhao, Cong Xue, Wei Jiang, Hong-Yun Zhao, Yan Huang, Kristin Feenstra, James H. Resau, Chao-Nan Qian, Li Zhang:Predictive value of intratumoral microvascular density in patients with advanced non-small cell lung cancer receiving chemotherapy plus bevacizumab.Journal of Thoracic Oncology2012; Vol 7(1):71-75(SCI=3.66)
      51. Li Zhang, Shenglin Ma, Xiangqun Song, Baohui Han, Ying Cheng, Cheng Huang, Shujun Yang, Xiaoqing Liu, Yunpeng Liu, Shun Lu, Jie Wang, Shucai Zhang, Caicun Zhou, Xiangwei Zhang, Nobuya Hayashi, Mengzhao Wang: Efficacy and tolerability data from a randomised, placebo-controlled, parallel-group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804) Lancet Oncology 2012;Vol 13:466-475 (SCI=22.589)
      52.Pei-Yu Huang, Yan Li, Hai-Qiang Mai, Rong-Zhen Luo, Yu-Chen Cai, Li Zhang: Expression of ERCC1 predicts clinical outcome in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy. Oral Oncology 2012; Vol 48(10):964-968 (SCI=2.857)
      53. Cong Xue, Zhihuang Hua, Wei Jiang, Yuanyuan Zhao, Fei Xu, Yan Huang, Hongyun Zhao, Jingxun Wu, Yang Zhang, Liping Zhao, Jing Zhang, Likun Chen, Li Zhang: National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China. Lung Cancer 2012; Vol 77(2):371-375 (SCI=3.43)
      54. Cong Xue, Xi Wang, Roujun Peng, Yanxia Shi, Tao Qin, Donggen Liu, Xiaoyu Teng, Shusen Wang, Li Zhang and Zhongyu Yuan: Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. Cancer Science 2012;Vol 103(9):1679-1687(SCI=3.325)
      55. Yang Zhang, Liping Zhao, Peiyu Huang, Jingxun Wu, Fenghua Wang, Yan Huang, Li Zhang: Open-Label Single-Arm Phase II Study of Pemetrexed in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma Who Have Had Prior Platinum Based Chemotherapy. Cancer Chemotherapy and Pharmacology2012; Vol 70(4):611-615(SCI=2.2)
      56.Jianwei Zhang, Yan Huang, Xiaoling Li, Ying Guo, Yuanyuan Zhao, Cong Xue, Zhihuang Hu, Li Zhang, Hongyun Zhao: The impact of tumor size change after target therapy on survival: analysis of patients enrolled onto three clinical trials of advanced NSCLCfrom one institution. Onco Targets and Therapy 2012, Vol 5:349–355 (SCI=1.26)
      57. Fei Xu, Jingxun Wu, Yuanyuan Zhao, Cong Xue, Wei Jiang, Liping Lin, Xuan Wu, Yachao Lu, Hua Bai, Jiasen Xu, Guanshan Zhu, Li Zhang: Comparison of different methods for detecting epidermal growth factor receptor mutationsin peripheral blood and tumor tissue of non-small cell lung cancer as a predictor of response to gefitinib. Onco Targets and Therapy 2012, Vol 5:439-447 (SCI=1.26)
      58. Yan Huang, Jing Zhang, Yuan-Yuan Zhao, Wei Jiang, Cong Xue, Fei Xu,Hong-Yun Zhao, Yang Zhang, Li-Ping Zhao, Zhi-Huang Hu, Zhi-Wen Yao,Qian-Yong Liu and Li Zhang: SPARC expression and prognostic value in non-small cell lung cancer. Chinese Journal of Cancer 2012; Vol31(11):541-548
      59. Zhao LP, Xue C, Zhang JW, Hu ZH, Zhao YY, Zhang J, Huang Y, Zhao HY, Zhang L. Expression of RRM1 and its association with resistancy to gemcitabine-based chemotherapy in advanced nasopharyngeal carcinoma. Chin J Cancer. 2012 Oct;31(10):476-8362.
      60. Hongyun Zhao, Yan Huang, Cong Xue,Yang Chen, Xue Hou, Ying Guo,Liping Zhao, Zhi huang Hu, Yujie Huang, Yongzhang Luo, Li Zhang: Prognostic significance of cell surface nucleolin expression in postoperative non-small cell lung cancer. PLos One 2013; Vol 8(1):e54674 (SCI=4.09)
      61.C. Xue, Y. Huang, P. Y. Huang, Q. T. Yu, J. J. Pan, L. Z. Liu, X. Q. Song, S. J. Lin, J. X. Wu, J. W. Zhang, H. Y. Zhao, F. Xu, J. L. Liu, Z. H. Hu, L. P. Zhao, Y. Y. Zhao, X Q . Wu, J. Zhang, Y. X. Ma,2&L. Zhang:Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma. Annals of Oncology 2013; Vol 24:1055-1061 (SCI=7.384)
      62.X. Wu, P. Y. Huang, P. J. Peng, L. X. Lu, F. Han, S. X. Wu, X. Hou, H. Y. Zhao, Y. Huang, W. F. Fang, Y. Y. Zhao, C. Xue, Z. H. Hu, J. Zhang, J. W. Zhang, Y. X. Ma, W. H. Liang, C. Zhao, L. Zhang: Long-term follow-up of a phase III study comparing radiotherapy with or without weekly oxaliplatin for locoregionally advanced nasopharyngeal carcinoma. Annals of Oncology 2013 Aug;24(8):2131-6;  (SCI=7.384)
      63. Hongyun Zhao, Yuanyuan Zhao, Ying Guo, Yan Huang, Suxia Lin, Cong Xue, Fei Xu, Yang Zhang, Liping Zhao, Zhihuang Hu, Li Zhang.: Clinical significance of the thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase mRNA expressions in hepatocellular carcinoma patients receiving 5-fluorouracil-based transarterial chemoembolization treatment. Onco Targets and Therapy2013; Vol 6:811-818 (SCI=2.073)
      64. Jian-Wei Zhang, Yuan-Yuan Zhao, Ying Guo, Cong Xue, Zhi-Huang Hu, Yan Huang, Hong-Yun Zhao, Jing Zhang, Xuan Wu, Wen-Feng Fang, Yu-Xiang Ma, Li Zhang.: The impact of both platinum-based chemotherapy and EGFR-TKIs on overall survival of advanced non--small cell lung cancer. Chinese journal of cancer 2013;Vol 32(1): (Accepted)
      65. Yuankai Shi*, Li Zhang (1)*, Xiaoqing Liu,et al. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. Lancet Oncol. 2013 Sep;14(10):953-61 (IF 22.589)
      66. Xuan Wu,Wenhua Liang,Xue Hou,Zhong Lin,Hongyun Zhao,Yan Huang,Wenfeng Fang,Yuanyuan Zhao,Jinxun Wu,Yunpeng Yang,Cong Xue,Zhihuang Hu,Jing Zhang,Jianwei Zhang,Yuxiang Ma,Ting Zhou,Tao Qin, LiZhang*. Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC. OncoTargets and Therapy 2013:6 1481–1491 (IF 2.073)
    电影票房  67. Wenfeng Fang,Jianwei Zhang,Wenhua Liang,Yan Huang,Yue Yan,Xuan Wu,Zhihuang Hu,Yuxiang Ma,Hongyun Zhao,Yuanyuan Zhao,Yunpeng Yang,Cong Xue,Jing Zhang,LiZhang* Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation. J Thorac Dis 2013;5(5):585-592

    第二、三作者及其他:
      1. E1B缺失腺病毒瘤內注射治療惡性腫瘤的安全性研究.《癌癥》2003, 22(3):310-313
      2. 423例非小細胞肺癌患者生存的多因素分析.《癌癥》2003, 22(6):624-628
      3. 表皮生長因子酪氨酸激酶抑制劑ZD1839對鼻咽癌細胞系的作用.《癌癥》2004, 23(5):540-544
      4. 表皮生長因子酪氨酸激酶抑制劑Gefitinib對鼻咽癌荷瘤裸鼠移植瘤生長作用的實驗研究.《癌癥》2004, 23(11s):1365-1369
      5. Xia ZJ, Chang JH, Zhang L, Jiang WQ, Guan ZZ, Liu JW, Zhang Y, Hu XH, Wu GH, Wang HQ, Chen ZC, Chen JC, Zhou QH, Lu JW, Fan QX, Huang JJ, Zheng Xiao: Phase III randomized Clinical Trial of Intratumoral Injection of E1B Gene-deleted Adenovirus (H101) Combined with Cisplatin-based Chemotherapy in Treating Squamous Cell Cancer of Head and Neck or Esophagus. Chinese Journal of Cancer 2004; Vol 23(12):1666-1670
      6. 雌、孕激素受體在乳腺癌原發灶及復發轉移灶之間的表達差異.《癌癥》2004, 23(12):1710-1713
      7. Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Ernberg I, Zeng YX.Comparison of Plasma Epstein–Barr Virus (EBV) DNA Levels and Serum EBV Immunoglobulin A/Virus Capsid Antigen Antibody Titers in Patients with Nasopharyngeal Carcinoma.  Cancer 2004;100:1162–70(SCI=4.8)
      8. Chen M, Chen YY, Bao Y, Xian CG, Liu GZ, Zhang L, Xu GC, Deng XW, Lu TX, Qian JY, Cui NJ. Neoadjuvant Chemotherapy Followed by Late-Course Accelerated Hyperfractionated Radiation Therapy for Locally Advanced Non-Small-Cell Lung Cancer: Long-Term Results of a Phase I/II Clinical Trial. Clinical Lung Cancer 2005, Vol 6(5):304-309(SCI=2.3)
      9. 羥基喜樹堿在腫瘤病人中的生物利用度研究.《中國臨床藥理學雜志》2005, 22(1):46-49
      10. Tony S.K. Mok, Kwok Chi Lam, Conrad Lee,Li Zhang, Herman Wong,Anthony T.C. Chan, Winnie Yeo, Anthony P.C. Yim, Karen Chak, Benny Zee: Phase II Randomized Study Comparing theToxicity Profile of Gemcitabine plus Cisplatin withGemcitabine plus Oral Etoposide in the Treatmentof Advanced Non-Small Cell Lung Cancer. Oncology 2005; Vol 68:485-492(SCI=1.9)
      11. 吉非替尼治療局部晚期或轉移性非小細胞肺癌在中國的臨床研究.《癌癥》2005,24(8):980-984
      12. 結直腸癌患者 DPD 水平與 5-FU血藥濃度療效及毒性的相關性研究.《癌癥》2005,24(4):483-487
      13. 柯薩奇病毒腺病毒受體的表達對基因工程腺病毒抗瘤活性的影響.《癌癥》2005,24(4):502-505
      14. 116例攜帶乙肝病毒的淋巴瘤患者化療后發生肝功能損害的臨床分析.《癌癥》2005,24(12):1507-1509
      15. 膀胱癌細胞CAR 的表達對E1B缺失腺病毒抗瘤活性的影響.《中山大學學報》2005,26(9):533-536
      16. Li YH, He YF, Jiang WQ, Wang FH, Lin XB,Zhang L, Xia ZJ, Sun XF, Huang HQ, Lin TY, He YJ, Guan ZZ.Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma.Cancer2006;106(6):1320-1325 (SCI=4.58)
      17. Fu Xiao-Hong, Wang Shu-Sen, Huang Yan, Wang Bo, Huang Hui-Qiang, Zhang Li, Sun Xiao-Fei, Xu Rui-Hua, Lin Tong-Yu: Feasibility Study of Application of International Prognostic Score on Prediction of Prognosis of Advanced Hodgkin’s Lymphoma.  Chinese Journal of Cancer 2006; Vol 25(8):1013-1018
      18.鼻咽癌組織中EGFR和p-ERK蛋白表達及檢測意義.《中華腫瘤雜志》2006,28(1):28-31
      19.誘導化療和紫杉醇每周同期化療結合三維適形放射治療不能手術的Ⅲ期非小細胞肺癌的初步結果.《癌癥》2006, 25( 10) : 1279- 1283
      20. 支氣管肺泡細胞癌之中國共識.《循證醫學》2006, 6( 4) : 227- 230
      21. 老年晚期非小細胞肺癌預后的影響因素分析.《廣州醫學院報》2007, 35( 5) : 48- 52
      22. CPT-11聯合 5-FU/CF(FOLFIRI)化療方案治療晚期結直腸癌.《 癌癥》 2007, 26( 8) : 905- 908
      23. 非小細胞肺癌孤立性轉移處理共識.《循證醫學》2007, 7(2):110-111
      24. Wu YL, Zhong WZ, Li LY, Zhang XT,Zhang L,Zhou CC, Liu W, Jiang B, Mu XL, Lin JY, Zhou Q, Xu CR, Wang Z, Zhang GC, Mok T:Epidermal Growth Factor Receptor Mutations and TheirCorrelation with Gefitinib Therapy in Patients withNon-small Cell Lung Cancer: A Meta-Analysis Based onUpdated Individual Patient Data from Six Medical Centersin Mainland China.  Journal of Thoracic Oncology 2007; Vol 2: 430–439 (SCI=1.43)
      25. FOLFOX 方案一線治療轉移性或復發性晚期大腸癌的療效分析.《中國腫瘤臨床》 2007, 34(24):1418-1421
      26. 吉西他濱聯合奧沙利鉑治療晚期胰腺癌患者的療效.《癌癥》2007,26(12):1381-1384
      27. 105例老年晚期非小細胞肺癌患者的回顧性分析.《臨床腫瘤學雜志》2008,13(5):409-412
      28. 非小細胞肺癌ⅢA期 N2 之處理.《循證醫學》2008,8(2):113-117
      29. Luo HY, Xu RH, Zhang L, Li YH, Shi YX, Lin TY, Han B, Wang F, Qiu MZ, He YJ, Guan ZZ:A Pilot Study of Oxaliplatin, Fluorouracil and Folinic Acid (FOLFOX-6) as First-Line Chemotherapy in Advanced or Recurrent Gastric Cancer.Chemotherapy 2008; Vol 54:228-235 (SCI=1.50)
      30. Mok TS, Wu YL, Yu CJ, Zhou C, Chen YM,Zhang L, Ignacio J, Liao M, Srimuninnimit V, Boyer MJ, Chua-Tan M, Sriuranpong V, Sudoyo AW, Jin K, Johnston M, Chui W, Lee JS:Randomized, Placebo-controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 2009; Vol 27:5080-5087 (SCI=17.3)
      31. Mok T, Wu YL, Zhang L: A small step towards personalized medicine for non-small cell lung cancer.Discov Med. 2009;Vol 8(43):227-31
      32. 孤立性肺結節的處理.《循證醫學》2009,9(4):244-246
      33. FOLFIRI 方案對草酸鉑治療失敗的晚期結直腸癌的療效分析.《癌癥》2009;Vol 28(9):913-918
      34. 局部晚期鼻咽癌誘導加同期化放療與誘導化放療的對照研究.《癌癥》2009;Vol 28(10):1033-1042
      35. Mok T, Wu YL, Au JS, Zhou C, Zhang L, Perng RP, Park K:Efficacy and Safety of Erlotinib in 1240 East/South-East Asian Patients with Advanced Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology 2010; Vol 5: 1609-161  (SCI=4.547)
      36. 貝伐珠單抗治療非小細胞肺癌的相關不良反應及處理原則.《中國肺癌雜志》2010,13(6):563-567
      37. 局限期小細胞肺癌放療靶區前瞻性隨機對照研究的初步報告.《中國肺癌雜志》 2010,13(7):691-6
      38. 紫杉醇聯合順鉑每周方案與三周方案治療老年晚期非小細胞肺癌的臨床隨機對照研究.《中國腫瘤防治雜志》 2010,17(18):1463-1466
      39. Herbst RS, Sun Y, Eberhardt WE, Germonpré P, Saijo N, Zhou C, Wang J, Li L, Kabbinavar F, Ichinose Y, Qin S,Zhang L, Biesma B, Heymach JV, Langmuir P, Kennedy SJ, Tada H, Johnson BE:Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer: a randomised, double-blind phase III trial (ZODIAC). Lancet Oncology 2010;Vol 11: 619–26 (SCI= 14.47)
      40.Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncology 2011;Vol 12:735-742 (SCI= 17.76)
      41.An X, Wang FH, Ding PR, Deng L, Jiang WQ, Zhang L, Shao JY, Li YH:Plasma Epstein-Barr virus DNA level strongly predicts survival inmetastatic/recurrentnasopharyngeal carcinoma treated with palliativechemotherapy.Cancer2011;Vol 117(16):3750-7. (SCI=5.131)
      42. Hu X, Bao Y, Zhang L, Guo Y, Chen YY, Li KX, Wang WH, Liu Y, He H, Chen M:Omitting elective nodal irradiation and irradiating postinduction versuspreinduction chemotherapy tumor extent for limited-stage small cell lung cancer: Interim analysis of a prospective randomized non-inferiority trial.Cancer2012; Vol 118(1):278-287 (SCI= 5.131)
      43.Xie M, Zhang L, He CS, Xu F, Liu JL, Hu ZH, Zhao LP, Tian Y:Activation of Notch-1 enhances epithelial-mesenchymal transition ingefitinib-acquired resistant lung cancer cells. J Cell Biochem.2012, Vol 113(5):1501-1513 (SCI= 3.12)
      44. Belani CP, Wu YL, Chen YM, Kim JH, Yang SH, Zhang L, Peterson P, Orlando M:Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Carein Patients from East Asia with Advanced, Nonsquamous Non-small Cell Lung Cancer:An Exploratory Subgroup Analysis of a Global, Randomized, Phase 3 Clinical Trial.Journal of Thoracic Oncology 2012; Vol 7(3):567-573
      45. Mian Xie, Li Zhang, Chao-Sheng He, Jin-Hui Hou, Su-Xia Lin, Zhi-Huang Hu, Fei Xu and Hong-Yun Zhao: Prognostic Significance of TAZ Expression in Resected Non-Small Cell Lung Cancer. Journal of Thoracic Oncology 2012; Vol 7(5):799-807
      46. Luis Paz-Ares, Bonne Biesma, David Heigener, Joachim von Pawel, Timothy Eisen, Jaafar Bennouna, Li Zhang, Meilin Liao, Yan Sun, Assad Chemaissani, SJM Gans, Constantinos Syrigos, Etienne Le Marie, Maya Gottfried, Johan Vansteenkiste, Vincente Alberola, Uwe Phillip Strauss, Elaine Montegriffo, Teng Jin Ong, Armando Santoro, on behalf of the NExUS Investigators Study Group: Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/ Cisplatin Alone or with Sorafenib for the First-Line Treatment of Advanced Non–Small Cell Lung Cancer. Journal of Clinical Oncology 2012; Vol 30:3048-3092 (SCI=18.37)
      47. Yin-Duo Zeng, Li Zhang, Hai Liao, Ying Liang, Fei Xu, Jun-Ling Liu, Xiao-Xiao Dinglin, Li-Kun Chen: Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study.Asian Pacific journal of cancer prevention2012; Vol 13(3):909-914.(SCI=0.66)
      48. Y. Sun, Y.-L. Wu, C.-C. Zhou, L. Zhang, L. Zhang, X.-Y. Liu, S.-Y. Yu, G.-L. Jiang, K. Li, S.-K. Qin, S.-L. Ma, L. Han, M. Quinlivan, M. Orlando, X.-Q. Zhang: Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: A randomized, open-label study. Lung Cancer2013; Vol 79(2):143-50, (SCI=3.43)
      49. Wu YL, Chu DT, Han B, Liu X, Zhang L, Zhou C, Liao M, Mok T, Jiang H, Duffield E, Fukuoka M.: Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China. Asia Pac J Clin Oncol. 2012; Vol 8(3):232-243 (SCI=0.58)
      50. 吉西他濱聯合長春瑞濱方案一線治療中國晚期非小細胞肺癌患者的多中心回顧性研究。《中國肺癌雜志》2012; Vol 15(5):281-6.
      51. 吉西他濱聯合長春瑞濱方案治療復治中國晚期非小細胞肺癌患者的多中心回顧性研究。《中國肺癌雜志》2012; 15(9):507-12.
      52. Fang Wang, Sha Fu, Qiong Shao, Yan-Bin Zhou, Xiao Zhang, Xu Zhang, Cong Xue, Jian-Guang Lin,Li-Xia Huang, Li Zhang, Wei-Min Zhang and Jian-Yong Shao:High EGFR copy number predicts benefits fromtyrosine kinase inhibitor treatment for non-smallcell lung cancer patients with wild-type EGFR. Journal of Translational Medicine 2013, Vol 11:90 (SCI=3.47)
      53. G. Chen, J. Feng, C. Zhou, Y.-L. Wu, X.-Q. Liu, C. Wang, S. Zhang, J. Wang, S. Zhou,S. Ren3, S. Lu, L. Zhang, C.-P. Hu, C. Hu, Y. Luo, L. Chen, M. Ye, J. Huang,X. Zhi, Y. Zhang, Q. Xiu, J. Ma, L. Zhang & C. You: Quality of life (QoL) analyses from OPTIMAL(CTONG-0802), a phase III, randomised, open-labelstudy of first-line erlotinib versus chemotherapy inpatients with advanced EGFR mutation-positivenon-small-cell lung cancer (NSCLC). Annals of Oncology, 2013 (SCI=7.384, Accepted)
      54. Yi-Long Wu, Jin Soo Lee, Sumitra Thongprasert, Chong-Jen Yu, Li Zhang, Guia Ladrera, Vichien Srimuninnimit, Virote Sriuranpong, Jennifer Sandoval-Tan, Yunzhong Zhu, Meilin Liao, Caicun Zhou, Hongming Pan, Victor Lee, Yuh-Min Chen, Yan Sun, Benjamin Margono, Fatima Fuerte, Gee-Chen Chang, Kasan Seetalarom, Jie Wang, Ashley Cheng, Elisna Syahruddin, Xiaoping Qian, James Ho, Johan Kurnianda, Hsingjin Eugene Liu, Kate Jin, Matt Truman, Ilze Bara, Tony Mok:Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncology 2013;Vol 14(8):777-786 (SCI=25.117)

      55.會議摘要(2003-2012):
      1. L. Zhang, P.J. Peng, C. Zhao: Randomized Phase II clinical study comparing standard RT with or without weekly Oxaliplatin in treatment of locally advanced NPC: preliminary result. Proc Am Soc Clin Oncol 2003; Vol 21:2003a (Poster)
      2. L. Zhang, Y. Zhang, ZZ. Guang: Phase II clinical study of Gemcitabine single agent for patients with advanced Nasopharyngeal Carcinoma (NPC) who failed to first line platinum-based chemotherapy. Proc Am Soc Clin Oncol 2004; Vol 22:5612a (Poster)
      3. L. Zhang, X. Zhang, ZK.Pan, X.Wang, N.Li, F. Xu, JH.Chang, ZZ. Guang: The status of epidermal growth factor receptor (EGFR) mutations at exon 19 and 21 in Chinese patients with NSCLC. Proc Am Soc Clin Oncol 2005; Vol 23:7097a (Poster)
      4. Y. Zhang, L. Zhang, N. Li, F. Xu, ZK. Pan, ZZ. Guang: Gemcitabine plus cisplatin versus gemcitabine plus vinorelbine in the treatment of advanced non-small cell lung cancer (NSCLC).      Proc Am Soc Clin Oncol 2005; Vol 23:7329a (Poster)
      5. Z Guan, L Zhang, L LI, G Jiang, X LIU, D Chu, W Li: A Chinese, Multicentre, Phase II Trial of Gefitinib (Iressa) in Patients with non-Small-Cell Lung Cancer who had Failed Previous Chemotherapy. 11th WCLC, Barcelona, Spain, July 3-6, 2005; Ab 2264
      6. L. Zhang, Li Ning, Zhang Xing, Pan Zhen-kui, Wang Xin, Xu Fei, Zhong-zhen Guan: Preliminary Analysis of biomarkers in plasma by SELDI to predict the response to EGFR Tyrosine Kinase Inhibitors (TKIs) in NSCLC patients.  Proc Am Soc Clin Oncol 2006; Vol 24:7189a (Poster)
      7. Xu Fei, Zhang Li, Li Su, Liao Hai: Phase I study of Recombinant adenovirus vector-mediated herpes simplex virus thymidine kinase gene and Ganciclovir administration in patients with malignant tumor. AACR 2007, Ab 1888
      8. B.R.Ghimire, L. Zhang, X. Zhang, S. Li, X. Hou, P.J. Peng: Effects of zoledronic acid on proliferation and synergy with cytotoxic agents in nasopharyngeal carcinoma cell lines.  AACR 2007,  Ab 3137
      9. X. Hou,L. Zhang, C. Zhao, L. Lu, F. Han, S. Li, P. Huang, H. Huang, Z. Guan: Clinical significance of Epstein-Barr virus DNA load detected pre- and post-radiotherapy in nasopharyngeal carcinoma patients.  Proc Am Soc Clin Oncol 2007; Vol 25:10558a(Poster)
      10. L. Zhang, X. Hou, H. Rao, J. Hou, R. Luo, H. Huang, P. Huang: Predictive significance of bone sialoprotein and osteopontin for bone metastases in respectable non-small cell lung cancer: A retrospective study. Proc Am Soc Clin Oncol 2007; Vol 25:7666a (Poster)
      11. R. Xu, B. Han, Y. Shi, J. Xiong, Y. Li, F. Wang, M. Qiu, W. Jiang, T. Lin, L. Zhang, Y. He: Phase II clinical trial of XELOX as first line treatment for patients with unresectable or metastatic gastric cancer. Proc Am Soc Clin Oncol 2007; Vol 25:15062a(Publication)
      12. Y. Wu, L. Zhang, J. Siu-Kie Au, A. Cheng, K. Park, H. Kim, V. Srimuninnimit, V. Sriuranpong, M. Lin, H. Kuo, on behalf of the Asia Pacific TRUST investigators: Safety of erlotinib in TRUST, a phase IV trial in patients with advanced non-small cell lung cancer (NSCLC): Initial results from the East/South East (E/SE) Asian subgroup. Proc Am Soc Clin Oncol 2007; Vol 25:18018a(Publication)
      13. Lin Li-Shan, Zhang Li, Zhang Yang, Wang Zhi-Qiang, Huang He, Zhao Hong-Yun, Guan Zhong-Zhen. Predictive factors of efficacy and survival in Chinese non-small cell lung cancer patients treated with gefitinib. Journal of Thoracic Oncology 2007; Vol 2:S748(Poster)
      14.L. Zhang, C. Zhao, B. R. Ghimire, Y. Guo, Z. Z. Guan: The Role of Concurrent Chemo-radiation in the Treatment of Locally Advanced Nasopharyngeal Carcinoma among Endemic Area: A Meta- analysis of the Phase III Randomized Trials. Proc Am Soc Clin Oncol 2008; Vol 26:6032a (Poster Discussion)
      15. J. S. Lee, J. Ignacio, C. Yu, C. Zhou, Y. Wu, Y. Chen, L. Zhang, K. Jin, M. Johnston, T. S. Mok.:FAST-ACT: A phase II randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2008; Vol 26:8031a (Poster Discussion)
      16. K. Lam, T. S. Mok, J. Lee, L. Zhang, Y. Wu, S. Lu, M. Liao, C. Yang, C. Zhou, M. Boyer.: A randomized phase II study of gemcitabine (G) vs gemcitabine/carboplatin (GC) as consolidation therapy to concurrent chemo-radiotherapy (CRT) for stage III non-small cell lung cancer (NSCLC): A Lung Cancer Research Group (LCRG) study. Proc Am Soc Clin Oncol 2008; Vol 26:7559a (Poster)
      17. Y. Y. Zhao, C. Q. Zhang, L. P. Lin, X. Wu, J. X. Wu, F. H. Wang, H. Y. Zhao, Z. Z. Guan, L. Zhang: The relationship between circulating VEGF level and outcome of advanced Chinese NSCLC treated with gefitinib. Proc Am Soc Clin Oncol 2008; Vol 27:19074a (Publication)
      18. J. X. Wu, H. Y. Zhao, Y. Zhang, Z. Z. Guan, L. Zhang: The relationship between change in tumor size and survival in advanced NSCLC treated with gefitinib. Proc Am Soc Clin Oncol 2008; Vol 26:19066a (Publication)
      19. L. Zhang, F.H. Wang, Y.H. Li, Y.J. He, Y. Guo, Z.Z. Guan: The role of oxaliplatin- containing regimens in the treatment of Chinese patients with advanced gastric cancer: a meta-analysis of randomized trials. ESMO 2008, (Poster 534)
      20. Y. Wu, T. Mok, D. Chu, B. Han, X. Liu, L. Zhang, C. Zhou, Y. Rukazenkov, E. Duffield, M. Fukuoka: Evaluation of clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) recruited in China in a phase III, randomized, open-label, first-line study in Asia of gefitinib (G) versus carboplatin/paclitaxel (C/P) (IPASS). Proc Am Soc Clin Oncol 2009; Vol 27:8041a (Poster)
      21. Y. Zhao, H. Liao, X. Hou, J. Sun, Y. Guo, S. Li, L. Zhang: A prospective, open-label, randomized phase II trial to evaluate the changes of bone resorption marker after administration of zoledronic acid (ZOL) in nasopharyngeal cancer (NPC) patients with bone metastases (BM). Proc Am Soc Clin Oncol 2009; Vol 27:6063a (Poster)
      22.J. Wu, H. Bai, G. Zhu, J. Xu, W. Jiang, L. Lin, C. Xue, L. Zhang: Comparison of different methods for detecting epidermal growth factor receptor mutations in peripheral blood as a predictor of response to gefitinib.Proc Am Soc Clin Oncol 2010; Vol 28:10557a (Poster)
      23.W. Huang, J. Wu, X. Lin, S. Li, R. Liu, W. Hu, Y. Xia, L. Zhang, W. Jiang, Z. Guan: A multicentre, open-label, randomized phase II trial of adenovirus-mediated endostatin gene therapy in combination with paclitaxel and cisplatin chemotherapy in advanced head and neck carcinoma: Preliminary results.Proc Am Soc Clin Oncol 2010; Vol 28: e16005(Publication)
      24.L. Zhang, S. Y. Yu, G. R. Xie, B. Xu, Z. Jiang, S. Lu, H. Wang, Y. Sun; A large, multicenter, retrospective epidemiological survey the incidence and treatment of bone metastatic disease in Chinese cancer patients. Proc Am Soc Clin Oncol 2010; Vol 28:e19612(Publication)
      25.H. Zhao, G. Chen, J. F. Feng, Y. Chen, Y. Zhang, X. Song, Y. Huang, L. Zhang; A phase II study of erlotinib plus capecitabine (XEL) as first line treatment for elderly patients (pts) with advanced adenocarcinoma of lung (ML 22206 study).Proc Am Soc Clin Oncol 2010; Vol 28:e18016(Publication)
      26.L. Zhang, M. Shenglin, X. Song, B. Han, Y. Cheng, C. Huang, S. Yang, X. Q. Liu, L. Yun-Peng, M. Wang, X. Zhang: Efficacy, tolerability and biomarker analyses from a phase III, randomized, placebo controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) in China (INFORM)  (C-TONG 0804). Proc Am Soc Clin Oncol 2011; Vol 29:LBA7511 (Oral)
      27.Y. Cheng, L. Zhang, H. Zhang, C. Zhou, B. Han, Y. Zhang, C. Huang, J. H. Chang, X. Song, J. Liang, H. Liang, J. Hu, S. Y. Yu, J. Chen, J. Wang, H. M. Pan, A. Carides, D. Chitkara: A 3-day oral aprepitant regimen provides superior prevention of CINV over standard therapy in Chinese patients receiving high-dose cisplatin. Proc Am Soc Clin Oncol 2011; Vol 29:9105 (Poster)
      28.Y. Sun, Y. Shi, L. Zhang, X. Q. Liu, C. Zhou, L. Zhang, D. Wang, Q. Li, S. Zhang, S. Qin, C. Hu, Y. Zhang, J. Chen, Y. Song, J. F. Feng, Y. Cheng, H. Zhang, Y. L. Wu, N. Xu, J. Zhou: A randomized, double-blind phase III study of icotinib versus gefitinib in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN).Proc Am Soc Clin Oncol 2011; Vol 29:7522(Poster)
      29.S. Lu, L. Zhang, Y. L. Wu, Y. Zhang, C. Zhou, G. Chen, M. Hou, X. Song, J. Wang:An observational study on the efficacy and safety of zoledronic acid (ZA) in non-small cell lung cancer (NSCLC) patients with bone metastases with high urine n-telopeptide (uNTX) at diagnosis (C-TONG 0801).Proc Am Soc Clin Oncol 2011; Vol 29: e19541(Publication)
      30.C. Zhou, Y. L. Wu, G. Chen, J. F. Feng, X. Q. Liu, C. L. Wang, S. Zhang, J. Wang, S. Zhou, S. Ren, S. Lu, L. Zhang:Updated efficacy and quality of life (QoL) analyses in OPTIMAL, a phase III, randomized, open-label study of first-line erlotinib vs gemcitabine/carboplatin in patients with EGFR activating-mutation positive (EGFR Act Mut+) advanced non-small cell lung cancer (NSCLC).Proc Am Soc Clin Oncol 2011; Vol 29:7520(Poster)
      31.  Yi-long Wu, Caicun Zhou, Li Zhang, Reury-Perng Perng, Tony Mok: Efficacy of erlotinib across clinical subgroups in Chinese patients and a broader Asian subpopulation with advanced non-small-cell lung cancer (NSCLC): sub-analysis of the TRUST study. Journal of Thoracic Oncology 2011; (ab P3.102) (Poster)
      32.C. Xue, J. J. Pan, X. Song, Y. Zhang, Q. Yu, S. Lin, J. Wu, Y. Zhao, W. Jiang, L. Zhang: Phase II study of combination of sorafenib with cisplatin and 5-fluorouracil as first-line treatment for patients with recurrent or metastatic nasopharyngeal carcinoma. Proc Am Soc Clin Oncol 2012;Vol 30:5538 (Poster)
      33.  Li Zhang, Meiqi Shi, Cheng Huang, Xiao-Qing Liu, Jian ping Xiong, Gongyan Chen, Wei Liu, Wenchao Liu, Yiping Zhang, Kai Li: A phase II, multi-center, Placebo controlled trial of apatinib in patients with advanced non-squamous non-small cell lung cancer (NSCLC) after 2 previous treatment regimens.Proc Am Soc Clin Oncol 2012;Vol 30:7548 (Poster)
      34.  Tony Mok, Yi-long Wu, Sumitra Thongprasert, Chong-Jen Yu,Li Zhang, Guia Ladrera, Vichien Srimuninnimit, Virote Sriuranpong, Jennifer Sandoval-Tan, Yunzhong Zhu, Meilin Liao, Caicun  Zhou, Hongming Pan, Victor Lee, Yuh-Min Chen, Yan Sun, Benjamin Margono, Kate Jin, Matt Truman, Jin Soo Lee: A randomized placebo-controlled phase 3 study of intercalated erlotinib with gemcitabine/platinum in 1st-line advanced non-small-cell lung cancer (NSCLC): FASTACT-2. Proc Am Soc Clin Oncol 2012; Vol 30:7519 (Poster Discussion)
      35. Caicun Zhou, Yi-long Wu, Xiaoqing Liu, Changli Wang, Gongyan Chen, Jifeng Feng, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren, Shun Lu, Li Zhang, Chenghong Hu, Yi Luo, Lei Chen, Ming Ye, Jianan Huang, Xiyuyi Zhi, Yiping Zhang, Qingyu Xiu: Overall survival (OS) results from OPTIMAL, a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2012; Vol 30:7520 (Poster Discussion)
      36. Liping Zhao, Wanli Liu, Chong Zhao, Xiang Guo, Yan Huang, Fei Xu, Zhihuang Hu, Zhiqiang Wang, Hongyun Zhao,Li Zhang: Pharmacokinetic and pharmacodynamic analysis of fluorouracil in nasopharyngeal cancer patients. Proc Am Soc Clin Oncol 2012;Vol 30:e13021 (Publication)
      37. Pierre Ferre, Zhimin Shao, Zefei Jiang, Dafang Zhong, Chen Xiaoyan, Jean-Philippe Burillon, Aurélie Petain, Grégoire Zorza, Li Zhang:Is vinorelbine pharmacokinetics modified in Asian patients when compared to Caucasian patients? Proc Am Soc Clin Oncol 2012; Vol 30:e13036 (Publication)
      38. Shun Lu, Lu Li, Yi Luo, Li Zhang, Zhiwei Chen, Wu Gang, Ping Chen, Cheng Huang, Shuliang Guo Sr., Yiping Zhang, Xiangqun Song, Meijun Lv, Wei Li, Chunhong Hu, Chengping Hu: Randomized phase II study of recombinant human endostatin in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer (NCT00912392). Proc Am Soc Clin Oncol 2012; Vol 30:7091(Poster)
      39. Yan Sun, Yuankai Shi, Li Zhang, Xiaoqing Liu, Caicun Zhou, LI Zhang, Dong Wang, Qiang Li, Shucai Zhang, Shukui Qin, Chunhong Hu, Yiping Zhang, Jianhua Chen, Yong Song, Ji Feng Feng, Ying Cheng, Helong Zhang, Yi Long Wu, Nong Xu, Jianying Zhou: Final overall survival and updated biomarker analysis results from the randomized phase III ICOGEN trial. Proc Am Soc Clin Oncol 2012;Vol 30:7559 (Poster)
      40. T.S.K. Mok, J.S. Lee, L. Zhang, C.-J. Yu, S. Thongprasert, G.E.I. Ladrera, V. Srimuninnimit, M.I. Truman, B. Klughammer, Y.-L. Wu: Biomarker analysis and overall survival (OS) from the randomized, placebo-controlled, phase 3, FASTACT-2 study of intercalated erlotinib with first-line chemotherapy in advanced Non-small cell lung cancer (NSCLC).ESMO 2012, (1226O)
      41. S. Yan, S. Yuankai, Z. Li, L. Xiaoqing, C. Zhou, Z. Li, W. Dong, L. Qiang, Z. Shucai, S. Qin:Final overall survival and update biomarker analysis results from the randomized phase III ICOGEN trial. ESMO 2012, (1269P)
      42. M. Xie and Z. Li:Preclinical anti-tumor activity of xl880 in nasopharyngeal carcinoma.ESMO 2012, (1027P)
    43. L.Zhao,W.Liu, X.Guo, C.Zhao, Y.Huang, F.Xuand L. Zhang:Pharmacokinetic and pharmacodynamic analysis of 5-fluorouracil in chinese head and neck cancer (hnc) patients.ESMO 2012, (1057P)
      44. L. Paz-Ares, V. Hirsh,L. Zhang, F. De Marinis, J.C-H. Yang, H. Wakelee,T. Seto, T. Schmelter, T.J. Ong, T.S.K. Mok, E.F. Smit: Monotherapy administration of sorafenib inpatients with non-small cell lung cancer:phase iii, randomized, double-blind,placebo-controlled MISSION trial.ESMO 2012, (LBA33 PR)
      45. Y. Wu,Z. Li, C. Zhou, L. Shun, Y. Zhang, M. Hou, W. Liu, J. Wang,G. Chen, Y. Zhou: Multi-center observational study on the diagnosisof non-small cell lung cancer bone metastasisand the efficacyand safety of bisphosphatestreatment (C-TONG 0801).ESMO 2012,(1359P)
      46. Q. Zhou, C. Zhou, G. Chen, Y. Cheng, C. Huang, L. Zhang, Y-L Wu:A phase II study of sorafenib monotherapy in thepatients with advanced or recurrentnon-small-cell lung cancer after failure ofEGFR-TKI (C-TONG0805).ESMO 2012,(1362TiP)
      47. Li Zhang, Shun Lu, Ying Cheng, Zhihuang Hu, Zhiwei Chen, Gongyan Chen, Xiaoqing Liu, Jinji Yang, Li Zhang, Jia Chen, Meijuan Huang, Min Tao, Gang Cheng, Cheng Huang, Caicun Zhou, Weimin Zhang, Hong Zhao:Different-dose docetaxel plus cisplatin as first-line chemotherapy and then maintenance therapy with single-agent docetaxel for advanced non-small cell lung cancer (TFINE study, C-TONG 0904). J Clin Oncol 31, 2013 (suppl; abstr 8015) (Poster Discussion)
      48. Wenhua Liang, Li Zhang: Multitargeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. J Clin Oncol 31, 2013 (suppl; abstr 8089) Poster
      49. Yan Huang, Li Zhang, Jian-ji Pan, Guoqing Hu, Wu Gang, Jian ping Xiong, Chaosu Hu, Lizhu Lin, Hao Yu, Haoyuan Jiang:A phase II, multicenter, open-label, single-arm trial of famitinib in patients with advanced recurrent and/or metastatic nasopharyngeal carcinoma (NPC) after two previous treatment regimens. J Clin Oncol 31, 2013 (suppl; abstr 6026)

    參加臨床研究的情況:
      作為主要研究者(Principle Investigator and/or Steering Committee member)的研究:
      1. A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib (BAY 43-9006) in chemonaïve patients with stage IIIB-IV non-small cell lung cancer (NSCLC) (NCT00558636). (Principle Investigator and Steering Committee member)
      2. A multicentre, double-blind randomised, phase III trial to assess the efficacy of Iressa 250mg for Maintenance therapy Following Induction Treatment for Advanced Non Small Cell Lung Cancer who have not experienced disease progression or unacceptable toxicity during chemotherapy(INFORM Study) (NCT00769639)(C-TONG 0804). (Principle Investigator and Steering Committee member)
      3. A phase II/III randomized, double-blind study of paclitaxel plus carboplatin in combination with vorinostat (MK-0683) or placeboin patients with stage IIIB (with pleural effusion) or stageIV non-small-cell lung cancer (NSCLC)(NCT00473889).(Steering Committee member)
      4. Efficacy and Safety Study of ZOMETA® in Treatment of High-Level NTX Non Small Cell Lung Cancer With Bone Metastasis (ZEST study) (NCT00762346).(Principle Investigatorand Steering Committee member)
      5. A Randomized, Placebo-controlled, Double-blind Phase III Study of the Effect of First-line Treatment With Intercalated Tarceva Versus Placebo in Combination With Gemcitabine/Platinum on Progression-free Survival in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (FAST-ACT-II) (NCT00883779).(Steering Committee member)
      6. International randomized study to evaluate the addition of docetaxel to thecombination of cisplatin-5-fluorouracil (TCF) vs. cisplatin-5-fluorouracil (CF)in the induction treatment of nasopharyngeal carcinoma (NPC) in childrenand adolescents(NCT00565448) (Steering Committee member)
      7. A Randomised phase II study of oral Vinorelbine in combination with cisplatin versus IV Vinorelbine in combination with cisplatin in unresectable localized or metastatic NSCLC (PM 0259 CA 225 J1).(Principle Investigator)
      8. Phase II study of combination of Sorafenib with cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who are failure of radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)(NCT00747799).(Principle Investigator)
      9. Study of Alimta in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) who have had prior platinum based chemotherapy(NCT00630149).(Principle Investigator)
      10. To evaluate the efficacy of ZOMETA® in treatment of bone metastases in patients with stage IV nasopharyngeal cancer (NCT00697619).(Principle Investigator)
      11. A Study of TX Regimen as First-Line Treatment in Elderly Patients With Stage IIIB/IV Adenocarcinoma Non-Small Cell Lung Cancer (NCSLC)(NCT00816868).(Principle Investigator)
      12. A randomized, multi-centre, double-blind, placebo-controlled, parallel-group comparison study to investigate the safety, tolerability and efficacy of MK-0869 for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with high-dose cisplatin (NCT00952341).(Principle Investigator)
      13. A randomized, multi-centre open-label phase III study of first line treatment using pemetrexed/cisplatin versus gemcitabine/cisplatin in non-squamous lung cancer (NCT01194453).(Principle Investigator)
      14. A Study of ASA404 or Placebo in Combination With Docetaxel in Second-Line Treatment for (Stage IIIb/IV) Non-Small Cell Lung Cancer (ATTRACT-2)(NCT00738387)(Steering Committee member)
      15. A Phase III, Multi-centre, Placebo-controlled Trial of Sorafenib (BAY 43-9006) in Patients With Relapsed or Refractory Advanced Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC) After 2 or 3 Previous Treatment Regimens.(MISSION trial) (NCT00863746).(Steering Committee member)
      16. GSK1572932A Antigen-Specific Cancer Immunotherapeutic as AdjuvantTherapy in Patients With Resectable MAGE-A3 Positive NSCLC (NCT00480025).(Steering Committee member)
      17. Gefitinib 500mg versus 250mg in patients with Non-Small Cell Lung Cancer (NSCLC) with stable disease after a month treatment of Gefitinib 250mg (NCT01017679).(Principle Investigator)
      18. A Phase III, Randomized, Double-blinded,Multi-center Study to Assess the Efficacy of Icotinib (ICOGEN?)versus Gefitinib in Patients with Locally Advanced or Metastatic (Stage IIIb–IV) Non-small Cell Lung Cancer (NSCLC) after Failure of 1st/2 Line Chemotherapy (ChiCRT-TRC-00000505)(NCT01040780).(Co-Principle Investigator)
      19. Taxotere Combined with Cisplatin for First-line chemotherapy with different dose and then maintenance therapy (C-TONG0904)  (NCT01038661,TrialTroveID-120637). (Principle Investigator)
      20. A study of Apatinib in Patients with Advanced Non-squamous Non-small Cell Lung Cancer(Phase II) ( NCT001270386).(Principle Investigator)
      21. Apatinib in the Treatment of Advanced Non-squamous Non-small Cell Lung Cancer(Phase III)( NCT01287962).(Principle Investigator)
      22. Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography (NCT01347424). (Principle Investigator)
      23. A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid Tumors (NCT01148615).(Principle Investigator)
      24. Famitinib in Treating Patients With Recurrent and/or Metastatic nasopharyngeal carcinoma (NCT01392235). (Principle Investigator)
      25. A randomized, control, multicenter phase III clinical trial comparing gemcitabine and cisplatin with 5-Fu and cisplatin in the treatment of  recurrent  or metastatic nasopharyngeal carcinoma (NPC) (NCT01528618). (Principle Investigator)
      26. Randomized Double-Blind Trial of Prophylactic EVOZAC® Calming Skin Spray for EGFR-TKIs Associated Rash Eruption in NSCLC (NCT01528488). (Co-Principle Investigator)
      27. A Phase I Study of continuous intravenous infusion Endostatin plus AC Regimen intreatingPatients With Advanced Adenocarcinoma of Lung(NCT01531790). (Principle Investigator)
    电影票房  28. Dose Escalation and PK Study of  M2ES  in Subjects With Advanced Solid Tumors.( NCT01226030) (Principle Investigator)


    作為參加者的研究(Participant Trail):
      1. International, randomized, open-label, phase IIItrial of paclitaxel/carboplatin plus PF 3512676 Versuspaclitaxel/carboplatin aloneasfirst-linetreatment ofpatients with advanced non-small cell lung cancer.(NCT00254891)
      2. A Randomized, double-blind study to evaluate the effect of Tarceva or placebo following platinum-based chemotherapy on overall survival and disease progression in patients with advanced, recurrent or metastatic Non-small Cell Lung Cancer (NSCLC) who have not experienced disease progression (STARTUN) (NCT00556712).
      3. An open-label, randomized study to evaluate the effect of Tarceva, compared with Alimta (Pemetrexed) or Taxotere (Docetaxel),on survival in patients with advanced, recurrent or metastatic Non-small Cell Lung Cancer who have experienced disease progression during platinum-based chemotherapy (TITAN) (NCT00556322).
      4. A phase III, randomized, double-blinded, multi-center study to assess the efficacy of docetaxel (TAXOTERE?) in combination with ZD6474 (ZACTIMA?) versus docetaxel (TAXOTERE?) in combination with placebo in patients with locally advanced or metastatic (Stage IIIb–IV) non-small cell lung cancer (NSCLC) after failure of 1st line anti-cancer therapy(NCT00312377)
      5. OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer(TRUST trial) (NCT00036647).
      6. Open-label study of bevacizumab (Avastin®) in combination withplatinum-containing chemotherapy as first-line treatment ofpatients with advanced or recurrent non-squamous non-smallcell lung cancer (NSCLC) (SAiL Study) (NCT00700180).
      7. Phase III, randomised, open-label, first-line study of gefitinib(G) Vs carboplatin/ paclitaxel (C/P) in clinicallyselectedpatients with advanced non-small-cell lung cancer (NSCLC)(IPASS Study) (NCT00322452).
      8. A Randomized Phase II Study of Gemcitabine (G) versus Gemcitabine/Carboplatin (GC) as Consolidation Therapy to Concurrent Chemo-radiotherapy (CRT) for Stage III Non-Small Cell Lung Cancer (NSCLC): A Lung Cancer Study Group (LCRG) Study.
      9. FAST-ACT: a phase II randomized double-blind trial of sequential erlotinib and chemotherapy as 1st-line treatment in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC)(NCT00940875).
      10. A trial comparing gemcitabine, cisplatin and sorafenib to gemcitabine, cisplatin and placebo in first-line treatment of stage IIIb with effusion and stage IV non-small cell lung cancer (NSCLC) (NExUS study,NCT00449033).
      11. Bisphosphonates Lung cancer Efficacy and Safety Trial (BLEST study)(NCT00765687).
      12. Randomized, Open-Label, phase 3 Trial Comparing Amrubicin Combined With Cisplatin Versus EP as First-Line Treatment in Patients With Extensive Disease SCLC (NCT00660504)
      13. A Multi-Center Phase III Randomized, Double-Blind Placebo-Controlled Study of the Cancer Vaccine Stimuvax® (BLP25 Liposome Vaccine) in NSCLC Subjects with Unresectable Stage III Disease. (NCT00409188).
      14. A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Locally Advanced or Metastatic (Stage IIIb/IV) Non-Small Cell Lung Cancer (NSCLC)(ATTRACT-1)(NCT00662597).
      15. An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The AnaplasticLymphoma Kinase (ALK) Gene(NCT00932451 ).
      16. An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving the Anaplastic Lymphoma Kinase (ALK) Gene(NCT00932893).
      17. An Investigational Drug, Crizotinib (PF-02341066), Is Being Studied In Tumors, Except Non-Small Cell Lung Cancer, That Are Positive For Anaplastic Lymphoma Kinase(ALK)( NCT01121588)
      18. LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer  (NCT00805194)
      19. A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors (NCT01626209)
      20. LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy (NCT01523587)
      21. LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung ( NCT01466660)
      22. A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer ( H3E-CR-JMIT)  (NCT01469000)
      23. A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients ( NCT01639001)
      24. Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) (RADIANT-4) (NCT01524783)
      25. Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer (NCT01297491)
      26. A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment (NCT01610336)
       27.Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone(NCT01450761)
       28. Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin (NCT01285609)

    參加獨立數據管理委員會(IDMC)
      1. A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study of Lapatinib (GW572016) in Combination with Paclitaxel versus Paclitaxel plus Placebo in Subjects with ErbB2 Amplified Metastatic Breast Cancer(IDMC member)
      2. LUX-Lung 6 study: A randomized, open-label, phase III study of BIBW 2992 versus chemotherapy as first-line treatment for patients with Stage IIIB or IV adenocarcinoma of the lung harbouring an EGFR activating mutation(IDMC member)
      3. INSPIRE study: A multi-national, double-blind, placebo-controlled,randomized, phase III clinical trial of the cancervaccine Stimuvax® (L-BLP25 or BLP25 liposomevaccine) in Asian subjects with stage III,unresectable, non-small cell lung cancer (NSCLC)who have demonstrated either stable disease orobjective response following primarychemo-radiotherapy.(IDMC member)
      4. The controlled trial of Tegafur, Gimeracil and Oteracil Potassium Capsule plus Cisplatin in untreated patients with advanced lung cancer(IDMC member)
      5. A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care (BSC) versus placebo plus BSC in Asian subjects with metastatic colorectal cancer (CRC) who have progressed after standard therapy (IDMC Chairmen)


    更新時間:2018年9月3日

訪客通道
員工通道
關注腫瘤醫院
留言建議 ×